Status:

COMPLETED

Amino Acid Kinetics of GMP-AA in Healthy Human Volunteers

Lead Sponsor:

Birmingham Women's and Children's NHS Foundation Trust

Conditions:

Phenylketonurias

Eligibility:

All Genders

18-50 years

Phase:

NA

Brief Summary

Children with phenylketonuria (PKU) are treated with a special diet supplemented with a synthetic protein based on amino acids. These have a poor taste and are inefficiently used by the body. A differ...

Detailed Description

In the USA, casein glycomacropeptide (CGMP), a low phenylalanine (Phe) 64-amino acid peptide derived from cheese whey, is widely promoted as a low Phe protein substitute in phenylketonuria (PKU). Prot...

Eligibility Criteria

Inclusion

  • Male and female healthy subjects without PKU;
  • 18 to 50 years of age;
  • Female subjects with a negative urine pregnancy test prior to entry into the study and who are practicing an adequate method of birth control during the study;
  • Good general health status proven by medical history and clinical laboratory values within normal limits or considered not clinically significant by the investigator;
  • Non-smokers or not current smokers;
  • Body mass index (BMI) between 18 and 30 kg/m2 and weight (kg)
  • No existence of disorders or any comorbidity.
  • Willing to follow the study protocol and to take the study products;
  • Able to understand study procedures and sign informed consent.

Exclusion

  • History of alcohol or drugs abuse;
  • Smokers;
  • Women who are pregnant, breast feeding, or planning to become pregnant during the course of the study;
  • Received an investigational drug or device within 30 days (or 5 half-lives, whichever is longer) of dosing;
  • Existence of any disorder, food allergy or comorbidity (clinically significant including gastrointestinal, renal, pulmonary, hepatic, cardiovascular and endocrine disorders) - to be decided by investigator from medical history;
  • Current illness or infection that could interfere with the study;
  • Use of laxatives;
  • Use of antibiotics in the last 3 months;
  • Use of medication that could influence protein metabolism (like growth hormone, anabolic steroids, hormone replacement) - to be judged by the investigator;
  • Participation in any clinical trial in the last 3 months;
  • Blood donation within the past 3 months;
  • On a medically prescribed diet;
  • Unable to follow the study protocol or provide consent;
  • Unable to take or tolerate one of the study products.

Key Trial Info

Start Date :

October 18 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 31 2023

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT05971563

Start Date

October 18 2022

End Date

August 31 2023

Last Update

March 4 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospitals Birmingham NHS Foundation Trust

Birmingham, West Midlands, United Kingdom, B15 2TT